[1]

Richter S, Wuest F. 18F-labeled peptides: the future is bright[J/OL]. Molecules, 2014, 19(12): 20536−20556[2020-12-24]. https://www.mdpi.com/1420-3049/19/12/20536. DOI: 10.3390/ molecules191220536.
[2] 张晓, 兰晓莉, 胡帆, 等.  点击化学在分子影像学中的应用和进展[J]. 国际放射医学核医学杂志, 2016, 40(3): 196-201.   doi: 10.3760/cma.j.issn.1673-4114.2016.03.008
Zhang X, Lan XL, Hu F, et al.  Applications and advances of click chemistry in molecular imaging[J]. Int J Radiat Med Nucl Med, 2016, 40(3): 196-201.   doi: 10.3760/cma.j.issn.1673-4114.2016.03.008
[3] Kumar K, Ghosh A.  18F-AlF labeled peptide and protein conjugates as positron emission tomography imaging pharmaceuticals[J]. Bioconjug Chem, 2018, 29(4): 953-975.   doi: 10.1021/acs.Bioconjchem.7b00817
[4] Cleeren F, Lecina J, Bridoux J, et al.  Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method[J]. Nat Protoc, 2018, 13(10): 2330-2347.   doi: 10.1038/s41596-018-0040-7
[5] Liu SL, Liu HG, Jiang H, et al.  One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging[J]. Eur J Nucl Med Mol Imaging, 2011, 38(9): 1732-1741.   doi: 10.1007/s00259-011-1847-4
[6] Wan WX, Guo N, Pan DH, et al.  First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination[J]. J Nucl Med, 2013, 54(5): 691-698.   doi: 10.2967/jnumed.112.113563
[7] Zhang H, Liu N, Gao S, et al.  Can an 18F-ALF-NOTA-PRGD2 PET/CT scan predict treatment sensitivity to concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma?[J]. J Nucl Med, 2016, 57(4): 524-529.   doi: 10.2967/jnumed.115.165514
[8] Li L, Ma L, Shang DP, et al.  Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response[J]. Eur J Nucl Med Mol Imaging, 2019, 46(4): 940-947.   doi: 10.1007/s00259-018-4143-8
[9] Pan DH, Yan YJ, Yang RH, et al.  PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN[J]. Contrast Media Mol Imaging, 2014, 9(5): 342-348.   doi: 10.1002/cmmi.1583
[10] Carlucci G, Kuipers A, Ananias HJK, et al.  GRPR-selective PET imaging of prostate cancer using [18F]-lanthionine-bombesin analogs[J]. Peptides, 2015, 67: 45-54.   doi: 10.1016/j.peptides.2015.03.004
[11] Ferlay J, Colombet M, Soerjomataram I, et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018[J]. Eur J Cancer, 2018, 103: 356-387.   doi: 10.1016/j.ejca.2018.07.005
[12] Boschi S, Lee JT, Beykan S, et al.  Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand[J]. Eur J Nucl Med Mol Imaging, 2016, 43(12): 2122-2130.   doi: 10.1007/s00259-016-3437-y
[13] Liu TL, Liu C, Xu XX, et al.  Preclinical evaluation and pilot clinical study of Al18F-PSMA-BCH for prostate cancer PET imaging[J]. J Nucl Med, 2019, 60(9): 1284-1292.   doi: 10.2967/jnumed.118.221671
[14] Hope TA, Bergsland EK, Bozkurt MF, et al.  Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors[J]. J Nucl Med, 2018, 59(1): 66-74.   doi: 10.2967/jnumed.117.202275
[15] Long TT, Yang NG, Zhou M, et al.  Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms[J]. Clin Nucl Med, 2019, 44(6): 452-458.   doi: 10.1097/RLU.0000000000002578
[16] Pauwels E, Cleeren F, Tshibangu T, et al.  [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients[J]. Eur J Nucl Med Mol Imaging, 2020, 47(13): 3033-3046.   doi: 10.1007/s00259-020-04918-4
[17] 邢宇, 赵新明.  放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J]. 国际放射医学核医学杂志, 2016, 40(2): 139-144.   doi: 10.3760/cma.j.issn.1673-4114.2016.02.011
Xing Y, Zhao XM.  Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J]. Int J Radiat Med Nucl Med, 2016, 40(2): 139-144.   doi: 10.3760/cma.j.issn.1673-4114.2016.02.011
[18] Zhang JM, Zhao XM, Wang SJ, et al.  Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with 99mTc-peptide-ZHER2:342[J]. Nucl Med Biol, 2015, 42(6): 541-546.   doi: 10.1016/j.nucmedbio.2015.02.002
[19] Jiao HL, Zhao XM, Liu JH, et al.  In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model[J]. Nucl Med Biol, 2019, 68/69: 31-39.   doi: 10.1016/j.nucmedbio.2018.11.004
[20] Han JY, Zhao Y, Zhao XM, et al.  Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2: V2-pemetrexed in lung adenocarcinoma xenografts[J]. Invest New Drugs, 2020, 38(4): 1031-1043.   doi: 10.1007/s10637-019-00876-3
[21] Heskamp S, Laverman P, Rosik D, et al.  Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer[J]. J Nucl Med, 2012, 53(1): 146-153.   doi: 10.2967/jnumed.111.093047
[22] Glaser M, Iveson P, Hoppmann S, et al.  Three methods for 18F labeling of the HER2-binding affibody molecule ZHER2: 2891 including preclinical assessment[J]. J Nucl Med, 2013, 54(11): 1981-1988.   doi: 10.2967/jnumed.113.122465
[23]

Xu YP, Bai ZC, Huang QH, et al. PET of HER2 expression with a novel 18FAl labeled affibody[J/OL]. J Cancer, 2017, 8(7): 1170−1178[2020-12-24]. https://www.jcancer.org/v08p1170.htm. DOI: 10.7150/jca.18070.
[24] Loktev A, Lindner T, Mier W, et al.  A tumor-imaging method targeting cancer-associated fibroblasts[J]. J Nucl Med, 2018, 59(9): 1423-1429.   doi: 10.2967/jnumed.118.210435
[25] Kratochwil C, Flechsig P, Lindner T, et al.  68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J]. J Nucl Med, 2019, 60(6): 801-805.   doi: 10.2967/jnumed.119.227967
[26] Watabe T, Liu YW, Kaneda-Nakashima K, et al.  Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models[J]. J Nucl Med, 2020, 61(4): 563-569.   doi: 10.2967/jnumed.119.233122
[27] Lindner T, Altmann A, Krämer S, et al.  Design and development of 99mTc-labeled FAPI tracers for SPECT imaging and 188Re therapy[J]. J Nucl Med, 2020, 61(10): 1507-1513.   doi: 10.2967/jnumed.119.239731
[28] Giesel FL, Adeberg S, Syed M, et al.  FAPI-74 PET/CT using either 18F-AlF or cold-kit 68Ga-labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients[J]. J Nucl Med, 2021, 62(2): 201-207.   doi: 10.2967/jnumed.120.245084
[29] Calais J, Mona CE.  Will FAPI PET/CT replace FDG PET/CT in the next decade? point—an important diagnostic, phenotypic and biomarker role[J]. AJR Am J Roentgenol, 2021, 216(2): 305-306.   doi: 10.2214/AJR.20.24302